Genetic alteration in drug resistance markers of Plasmodium falciparum

Indian Journal of Medical Research

Volumn 121, Issue 1, 2005, Pages 13-22

  Sharma, Y D ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Drug resistance; Malaria; Molecular epidemiology; Molecular markers; Point mutations

Indexed keywords

CHLOROQUINE; MOLECULAR MARKER; PYRIMETHAMINE; SULFADOXINE;

ANTIGENIC VARIATION; DRUG SURVEILLANCE PROGRAM; GENE MUTATION; GENETIC ANALYSIS; GENOME; HEALTH CARE POLICY; LIFE CYCLE ASSESSMENT; MALARIA; MARKER GENE; NONHUMAN; PLASMODIUM FALCIPARUM; POINT MUTATION; PREDICTION; REVIEW; SURVIVAL RATE;

ANIMALS; DRUG RESISTANCE; GENETIC MARKERS; PLASMODIUM FALCIPARUM; POINT MUTATION;

EID: 14544286523     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Payne D. Spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today 1987; 3: 241-6.
2. Moore DV, Lanier JE. Observations on two Plasmodium falciparum infections with an abnormal response to chloroquine. Am J Trop Med Hyg 1961; 10: 5-9.
3. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184: 770-6.
4. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2: 209-18.
5. Misra SP. In vivo resistance to chloroquine and sulfadoxine/pyrimethamine combination in Plasmodium falciparum in India. Proc Nat Acad Sci India 1996; 66: 123-38.
6. Kondrachine A, Trigg PI. Global overview of malaria. Indian J Med Res 1997; 106: 39-52.
7. Sharma YD, Biswas S, Pillai CR, Ansari MA, Adak T, Devi U. High prevalence of chloroquine resistant Plasmodium falciparum infection in Rajasthan epidemic. Acta Trop 1996; 62: 135-41.
8. Sharma VP. Current scenario of malaria in India. Parasitologia 1999; 41: 349-53.
9. Biggs BA, Kemp DJ, Brown GV. Subtelomeric chromosome deletions in field isolates of Plasmodium falciparum and their relationship to loss of cytoadherence in vitro. Proc Natl Acad Sci USA 1989; 86: 2428-32.
10. Sharma YD. Knob proteins in falciparum malaria. Indian J Med Res 1997; 106: 53-62.
11. Pologe LG, Ravetch JV. A chromosomal rearrangement of a P. falciparum histidine-rich protein gene is associated with the knobless phenotype. Nature 1986; 322: 474-7.
12. Kant R, Sharma YD. Allelic forms of the knob associated histidine-rich protein gene of Plasmodium falciparum. FEBS Lett 1996; 380: 147-51.
13. Ranjit MR, Sharma YD. Genetic polymorphism of falciparum malaria vaccine candidate antigen genes among field isolates in India. Am J Trop Med Hyg 1999; 61: 103-8.
14. Bhutani N, Ranjit MR, Yameen M, Singh N, Dev V, Pillai CR, et al. Genetic diversity among field isolates of Plasmodium falciparum in India. Curr Sci 1998; 75: 160-3.
15. Recker M, Nee S, Bull PC, Kinyanjui S, Marsh K, Newbold C, et al. Transient cross-reactive immune responses can orchestrate antigenic variation in malaria. Nature 2004; 429: 555-8.
16. Borst P. Bitter W, McCulloch R, van Leeuwen F, Rudenko G. Antigenic variation in malaria. Cell 1995; 82: 1-4.
17. Hayton K, So XZ. Genetic and biochemical aspects of drug resistance in malaria parasites. Curr Drug Targets Infect Disord 2004; 4: 1-10.
18. Le Bras J, Durand R. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam Clin Pharmacol 2003; 17: 147-53.
19. Warhurst DC. Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Sci Prog 2002; 85: 89-111.
20. Wernsdorfer WH, Noedl H. Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr Opin Infect Dis 2003; 16: 553-8.
21. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol 2003; 49: 977-89.
22. Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ, et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol 2004; 52: 985-97.
23. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001; 344: 257-63.
24. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, et al. Evidence for selection for the tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology 1997; 114: 205-11.
25. Wang P, Brooks DR, Sims PF, Hyde JE. A mutation specific PCR system to detect sequence variation in dihydropteroate synthetase gene of Plasmodium falciparum. Mol Biochem Parasitol 1995; 71: 115-25.
26. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997; 176: 1590-6.
27. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chloroproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002; 185: 380-8.
28. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant in mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 1997; 94: 1124-9.
29. Gyang FN, Peterson DS, Wellems TE. Plasmodium falciparum rapid detection of dihydrofolate reductase mutations that confer resistance to cycloguanil and pyrimethamine. Exp Parasitol 1992; 74: 470-2.
30. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reacation methods for surveillance in Africa. Am J Trop Med Hyg 1995; 52: 565-8.
31. Foote SJ, Thompson JK, Cowmanm AF, Kemp DJ. Amplification of the multi drug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 1989; 57: 921-30.
32. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 1990; 345: 255-8.
33. Su X, Kirkman LA, Fujioka H, Wellems TE. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant Plasmodium falciparum in Southeast Asia and Africa. Cell 1997; 91: 593-603.
34. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane proteins PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6: 861-71.
35. Wilson CM, Serrano AE, Wasley A, Bogenschutz MP, Shanker AH, Wirth DF. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science 1989; 224: 1184-6.
36. Wellems TE, Panton LJ, Gluzman IY, do Rosario VE, Gwadz RW, Walker-Jonah A, et al. Chloroquine resistance not linked to mdr like genes in a Plasmodium falciparum cross. Nature 1990; 345: 253-5.
37. Haruki K, Bray PG, Ward SA, Hommel M, Ritchie GY. Chloroquine resistance of Plasmodium falciparum: further evidence for a lack of association with mutations of the pfmdr1 gene. Trans R Soc Trop Med Hyg 1994; 88: 694.
38. Myrick A, Munasinghe A, Patankar S, Wirth DF. Mapping of the Plasmodium falciparum multidrug resistance gene 5′-upstream region, and evidence of induction of transcript levels by antimalarial drugs in chloroquine sensitive parasites. Mol Microbiol 2003; 49 671-83.
39. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403: 906-9.
40. Awad-el-Kariem FM, Miles MA, Warhurst DC. Chloroquine-resistant Plasmodium falciparum isolates from the Sudan lack two mutations in the pfmdr1 gene thought to be associated with chloroquine resistance. Trans R Soc Trop Med Hyg 1992; 86: 587-9.
41. Huaman MC, Roncal N, Nakazawa S, Long TT, Gerena L, Garcia C, et al. Polymorphism of the Plasmodium falciparum multidrug resistance and chloroquine resistance transporter genes and in vitro susceptibility to aminoquinolines in isolates from the Peruvian Amazon. Am J Trop Med Hyg 2004; 70: 461-6.
42. Adagu IS, Dias F, Pinheiro L, Rombo L, doRosario V, Warhurst DC. Guinea-Bissau: association of chloroquine resistance of Plasmodium falciparum with the Tyr 86 allele of the multiple drug resistance gene pfmdr1. Trans R Soc Trop Med Hyg 1996; 90: 90-1.
43. Adagu IS, Warhurst DC, Carucci DJ, Duraisingh MT. pfmdr1 mutations and chloroquine-resistance in Plasmodium falciparum isolates from Zaria, Nigeria. Trans R Soc Trop Med Hyg 1995; 89 132.
44. Basco LK, LeBras J, Rhoades Z, Wilson CM. Analysis of Pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from SubSaharan Africa. Mol Biochem Parasitol 1995; 74: 157-66.
45. Cox-Singh J, Singh B, Alias A, Abdullah MS. Assessment of the association between three pfmdr1 point mutations and chloroquine resistance in vitro of Malaysian Plasmodium falciparum isolates. Trans R Soc Trop Med Hyg 1995; 89: 436-7.
46. Gomez-Saladin E, Fryauff DJ, Taylor WR, Laksana BS, Susanti AI, Purnomo. Plasmodium falciparum mdr1 mutations and in vivo chloroquine resistance in Indonesia. Am J Trop Med Hyg 1999; 61 240-4.
47. Dorsey G, Kamya MR, Singh A, Rosenthal PJ. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis 2001; 183: 1417-20.
48. Pillai DR, Labbe AC, Vanisaveth V, Hongvangthong B, Pomphida S, Inkathone S et al. Plasmodium falciparum malaria in Laos: chloroquine treatment outcome and predictive value of molecular markers. J Infect Dis 2001; 183: 789-95.
49. Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF. Characterization of Plasmodium falciparum isolated from the Amazoan region of Brazil: evidence for quinine resistance. Am J Trop Med Hyg 1998; 58: 630-7.
50. Durand R, Gabbett E, Di Piazza JP, Delabre JF, LeBras J. Analysis of kappa and omega repeats of the cg2 gene and chloroquine susceptibility in isolates of Plasmodium falciparum from Sub-Saharan Africa. Mol Biochem Parasitol 1999; 101: 185-97.
51. McCutcheon KR, Veale RB, Frean JA, Markus MB. Rapid detection of cg2 polymorphisms in chloroquine-resistant and-sensitive isolates of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1999; 93: 326-8.
52. McCutcheon KR, Freese JA, Frean JA, Veale RB, Sharp BL, Marku MB. Chloroquine-resistant isolates of Plasmodium falciparum with alternative CG2 omega repeat length polymorphisms. Am J Trop Med Hyg 2000; 62: 190-2.
53. Sharma I, Aneja MK, Biswas S, Dev V, Ansari MA, Pasha ST, et al. Allelic variation in the cg2 gene does not correlate with chloroquine resistance among Indian Plasmodium falciparum isolates. Int J Parasitol 2001; 31: 1669-72.
54. Fidock DA, Nomura T, Cooper RA, Su X, Talley AK, Wellems TE. Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum. Mol Biochem Parasitol 2000; 110: 1-10.
55. Wellems TE, Walker-Jonah A, Panton LJ. Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc Natl Acad Sci USA 1991; 88: 3382-6.
56. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002; 298: 210-3.
57. Basco LK, Ringwald P. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon. J Infect Dis 2001; 183: 1828-31.
58. Chen N, Russell B, Staley J, Kotecka B, Nasveld P, Cheng Q. Sequence polymorphisms in pfcrt are strongly associated with chloroquine resistance in Plasmodium falciparum. J Infect Dis 2001; 183: 1543-5.
59. Vinayak S, Biswas S, Dev V, Kumar A, Ansari MA, Sharma YD. Prevalence of the K76T mutation in the pfcrt gene of Plasmodium falciparum among chloroquine responders in India. Acta Trop 2003; 87: 287-93.
60. Vathsala PG, Pramanik A, Dhanasekaran S, Devi CU, Pillai CR, Subbarao SK, et al. Widespread occurrence of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) gene haplotype SVMNT in P. falciparum malaria in India. Am J Trop Med Hyg 2004; 70: 256-9.
61. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 2003; 69: 558-63.
62. Chen N, Kyle DE, Pasay C, Fowler EV, Baker J, Peters JM, et al. pfcrt allelic types with two novel amino acid mutations in chloroquine-resistant Plasmodium falciparum isolates from the Philippines. Antimicrob Agents Chemother 2003; 47: 3500-5.
63. Babiker HA, Pringle SJ, Abdel-Muhsin A, Mackinnon M, Hunt P, Walliker D. High level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multi drug resistance gene pfmdr1. J Infect Dis 2001; 183: 1535-8.
64. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet 1999; 353 1965-7.
65. Tarimo DS, Minjas JN, Bygbjerg IC. Sulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy. Trop Med Int Health 2002; 7: 592-8.
66. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, Msokame C, et al. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2002; 67: 17-23.
67. Pinichpongse S, Doberstyn EB, Cullen JR, Yisunsri L, Thongsombun Y, Thimasarn K. An evaluation of five regimens for the outpatient therapy of falciparum malaria in Thialand 1980-81. Bull World Health Organ 1982; 60: 907-12.
68. Nwanyanwu OC, Ziba C, MacHeso A, Kazembe P. Efficacy of sulfadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old. Trop Med Int Health 2000; 5: 355-8.
69. Biswas S, Valecha N, Tyagi PK, Phookan S, Dev V, Sharma SK, et al. Assessment of therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine in uncomplicated falciparum malaria. J Vector Borne Dis 2003; 40: 92-9.
70. Basco LK, Same-Ekobo A, Ngane VF, Ndounga M, Metoh T, Ringwald P, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ 2002; 80: 538-45.
71. Schmidt-Ott R, Luckner D, Lehman LG, Lell B, Matousek P, Greve B, et al. Pyrimethamine/sulfadoxine for treating uncomplicated Plasmodium falciparum malaria in young children in Gabon. Trans R Soc Trop Med Hyg 1997; 91: 578-9.
72. Driessen GJ, van Kerkhoven S, Schouwenberg BJ, Bonsu G, Verhave JP. Sulfadoxine/pyrimethamine: an appropriate first-line alternative for the treatment of uncomplicated falciparum malaria in Ghanaian children under 5 years of age. Trop Med Int Health 2002; 7: 577-83.
73. Metzger W, Mordmuller B, Graninger W, Bienzle U, Kremsner PG. Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. J Antimicrob Chemother 1995; 36: 723-8.
74. Ejov MN, Tun T, Aung S, Sein K. Response of falciparum malaria to different antimalarials in Myanmar. Bull World Health Organ 1999; 77: 244-9.
75. Ronn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimehtamine in children in Tanzania. Trans R Soc Trop Med Hyg 1996; 90: 179-81.
76. Wernsdorfer WH. The development and spread of drug resistant malaria. Parasitol Today 1991; 7: 297-303.
77. Wolday D, Kibreab T, Bukenya D, Hodes R. Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg 1995; 89: 654-6.
78. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob Agents Chemother 2004; 48 2214-22.
79. Leartsakulpanich V, Imwong M, Pukrittayakamee S, White NJ, Snounou G, Sirawaraporn W, et al. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol Biochem Parasitol 2002; 119: 63-73.
80. Nirmalan N, Sims PF, Hyde JE. Quantitative proteomics of the human malaria parasite Plasmodium falciparum and its application to studies of development and inhibition. Mol Microbiol 2004; 52 1187-99.
81. Gatton ML, Martin LB, Cheng Q. Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother 2004; 48: 2116-23.
82. Nirmalan N, Sims PF, Hyde JE. Translational up-regulation of antifolate drug targets in the human malaria parasite Plasmodium falciparum upon challenge with inhibitors. Mol Biochem Parasitol 2004; 136: 63-70.
83. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, et al. Insights into antifolate resistance from malaria DHFR-TS structures. Nat Struct Biol 2003; 10: 357-65.
84. Sirawaraporn W, Sirawaraporn R, Yongkiettrakul S, Anuwatwora A, Rastelli G, Kamchonwongpaisan S, et al. Mutational analysis of Plasmodium falciparum dihydrofolate reductase: the role of aspartate 54 and phenylalanine 223 on catalytic activity and antifolate binding. Mol Biochem Parasitol 2002; 121: 185-93.
85. Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1990; 87: 3018-22.
86. Chusacultanachai S, Thiensathit P, Tarnchompoo B, Sirawaraporn W, Yuthavong Y. Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Mol Biochem Parasitol 2002; 120: 61-72.
87. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origin. Mol Biochem Parasitol 1997; 89: 161-77.
88. Ahmed A, Bararia D, Vinayak S, Yameen M, Biswas S, Dev V, et al. Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob Agents Chemother 2004; 48: 879-89.
89. McFadden GI, Roos DS. Apicomplexan plastids as drug targets. Trends Microbiol 1999; 7: 328-33.
90. Brown GM. The biosynthesis of folic acid. II. Inhibition by sulfonamides. J Biol Chem 1962; 237: 536-40.
91. Dieckmann A, Jung A. Mechanisms of sulfadoxine resistance in Plasmodium falciparum. Mol Biochem Parasitol 1986; 19: 143-7.
92. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997; 94: 13944-9.
93. Kublin JG, Witzig RS, Shankar AH, Zurita JQ, Gilman RH, Guarda JA, et al. Molecular assays for surveillance of antifolate-resistant malaria. Lancet 1998; 351: 1629-30.
94. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, Mosha F, et al. Antifolate antimalarial resistance in southeast Africa: a population based analysis. Lancet 2003; 361: 1174-81.